AIDS treatment
In a landmark study conducted at the Mildmay-Uganda Hospital from 2018 to 2023, researchers analyzed data from 235 people living with HIV (PLHIV) and found that early drug resistance mutations testing and individualized antiretroviral therapy (ART) can significantly improve HIV treatment outcomes. The study, led by Collins Ankunda and colleagues,
AIDS treatment
Research conducted by a team from the University of California San Francisco (UCSF) has found that early testing of infants exposed to HIV can significantly decrease mortality rates for those linked to HIV treatment. According to the study, infants exposed to HIV should be tested at 6 weeks of age,
AIDS treatment
The European AIDS Treatment Group has published promising results from a phase 2 trial combining lenacapavir (LEN) and two broadly neutralizing antibodies (bNAbs), teropavimab (TAB) and zinlirvimab (ZAB). The study, presented at EACS 2025, found that this combination produced a slightly lower average increase in CD4+ counts compared to a
AIDS treatment
The prevalence of skin conditions among people living with HIV remains significant, even in the era of highly effective antiretroviral therapy. A new study published through the DC Cohort, one of the largest HIV longitudinal studies in the United States, reveals that nearly half of participants experienced skin conditions. The
AIDS treatment
Researchers from the CALIBRATE study published final results in the journal AIDS, demonstrating that a long-acting injectable antiretroviral, lenacapavir, can maintain nearly 100% viral suppression rates when administered with daily antiretrovirals to individuals starting HIV treatment for the first time. The study's findings suggest that a twice-yearly first-line
AIDS treatment
The prevalence of skin conditions among people living with HIV remains significant, even in the era of highly effective antiretroviral therapy. A new study published through the DC Cohort, one of the largest HIV longitudinal studies in the United States, reveals that nearly half of participants experienced skin conditions. The
AIDS treatment
A new analysis has revealed that lenacapavir, a long-acting injectable for HIV prevention, could be produced for as little as $25 per person per year, potentially transforming global efforts to end the HIV epidemic. The study, co-authored by Andrew Hill and featured in The Lancet, demonstrates that generic production costs
AIDS treatment
MSF welcomes the release of new World Health Organization (WHO) HIV prevention guidelines recommending wider use of lenacapavir, an injectable version of pre-exposure prophylaxis (PrEP) that only needs to be administered two times per year. The organization is urging Gilead Sciences, the developer of lenacapavir, to make it more accessible
AIDS treatment
The Global Fund to Fight AIDS, Tuberculosis and Malaria has signed an access agreement with Gilead Sciences to procure lenacapavir, a long-acting injectable HIV prevention medication, for low- and middle-income countries. This groundbreaking deal will make lenacapavir available in these countries at the same time as in high-income countries, a
AIDS treatment
Researchers surveyed 150 individuals receiving long-acting injectable cabotegravir/rilpivirine at a Chicago clinic and found that almost all participants expressed high satisfaction with their HIV treatment and planned to continue, despite experiencing injection-site pain as a nearly universal side effect. The majority of participants were heterosexual Black men, and the
AIDS treatment
As Gilead Sciences expands lenacapavir, a long-acting HIV treatment, to 120 countries through voluntary licensing agreements with six generic manufacturers, the AIDS Healthcare Foundation (AHF) is highlighting the alarming exclusions of key HIV-affected countries in Latin America and others from the deal. According to AHF, this license excludes 2 million
AIDS treatment
In a significant move, Health Desk Stock Market Stats Hetero has announced a new partnership with Gilead Sciences Ireland UC to manufacture and distribute lenacapavir in 120 primarily low- and lower-middle-income countries (LMICs). This collaboration aims to broaden access to lenacapavir, an innovative HIV treatment used in combination with other
